What is claimed is:
1. A method of treating a subject suffering from an allergic condition, said method comprising administering to said subject a therapeutically effective amount of a pharmaceutical composition comprising a cathepsin S inhibitor.
2. A method according to claim 1, wherein the allergic condition is an atopic IgE-mediated allergic condition.
3. A method according to claim 1, wherein the allergic condition is selected from hay fever, asthma, atopic dermatitis, and a food allergy.
4. A method of claim 1, wherein said cathepsin S inhibitor is a compound of formula:
1
in which: n is 0 to 13;
A-B represents a linkage selected from C(O)NR3, CH2NR3, C(O)CH2 and NR3C(O), wherein R3 is hydrogen or as defined below;
X represents a bond, methylene or the linkage CH2CH(R4), wherein R4 is hydrogen, alkyl or arylalkyl;
Y is CH(R5) or N(R5), wherein R5 is hydrogen or as defined below;
Z is (CH2)2, C(R6)(R7) or N(R7), wherein R6 is hydrogen or methyl and R7 is as defined below;
Z1 is (CH2)2, C(R6)(R8) or N(R8), wherein R6 is hydrogen or methyl and R8 is as defined below; R1 is hydrogen, alkyloxycarbonylalkanoyl, alkyloxycarbonyl, alkanoyl (optionally substituted with a radical selected from carboxy, alkyloxycarbonyl and heterocycloalkylalkanoylamino), cycloalkylcarbonyl, heterocycloalkylcarbonyl (optionally substituted with a radical selected from hydroxy, alkyl, alkanoyl, alkyloxycarbonyl, arylalkyloxycarbonyl and heterocycloalkylcarbonyl), arylalkyloxycarbonyl, carbamoyl, alkylcarbamoyl, dialkylcarbamoyl, arylcarbamoyl, arylalkylcarbamoyl, arylalkanoyl, aroyl, alkylsulfonyl, dialkylaminosulfonyl, arylsulfonyl or heteroarylsulfonyl;
R7 and R8 are independently hydrogen, alkyl (optionally substituted with a radical selected from hydroxy, amino, alkylamino, dialkylamino, uriedo, mercapto, alkylthio, carboxy, carbamoyl, alkylcarbamoyl, dialkylcarbamoyl, alkylsulfonyl and guanidino, or a protected derivative thereof, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, a group selected from aryl and arylalkyl (which group is optionally substituted at its aryl ring with one to three radicals selected from hydroxy, amino, guanidino, halo, optionally halo-substituted alkyl, alkyloxy and aryl, or a protected derivative thereof) or together with an adjacent R3 or R5 forms a divalent radical selected from (C3-4)methylene and 1,2-phenylenedimethylene (which radical is optionally substituted with hydroxy, or a protected derivative thereof, or oxo); and
R2 is hydrogen, alkyl (optionally substituted with one or more radicals selected from amino, halo, hydroxy, alkyloxy, nitro, alkylsulfonyl and arylsulfonyl, or a protected derivative thereof, cycloalkyl, cycloalkylalkyl or a group selected from aryl and arylalkyl (which group is optionally substituted at its aryl ring with one to two radicals selected from amino, guanidino, halo, hydroxy, optionally halo-substituted alkyl, alkyloxy, nitro, alkylsulfonyl and arylsulfonyl, or a protected derivative thereof; or a pharmaceutically acceptable salt, isomer or mixture of isomers thereof.
5. The method of claim 4, wherein said cathepsin S inhibitor is a compound wherein Z is C(R6)(R7); n is 0; R3, R5 and R8 are each hydrogen; R1 is hydrogen, tert-butxoycarbonyl, benzyloxycarbonyl, biotinylaminohexanoyl, benzoyl, 1-piperiziny-carbonyl, 4-methyl-1-piperazinylcarbonyl or 4-morpholinylcarbonyl; R8 is butyl, 2-phenylethyl or 2-methylsulfonylethyl; R2 is phenyl, 1-naphthyl or 2-phenylethyl; and R7 is (C1-5)alkyl, 2-methylsulfonylethyl, optionally substituted benzyl, 1-naphthylmethyl, 2-naphthylmethyl, 3-pyridinylmethyl or 2-methylsulfonylethyl.
6. The method of claim 5, wherein said cathepsin S inhibitor is a compound wherein R1 is 1-piperizinylcarbonyl, 4-methyl-1-piperazincarbonyl or 4-morpholinylcarbonyl; R8 is 2-phenylethyl; R2 is phenyl or naphth-2-yl; and R7 is optionally substituted benzyl, 1-naphthylmethyl or 2-naphthylmethyl.
7. A method of claim 1, wherein said cathepsin S inhibitor is a compound of formula:
2
in which: n is 0 to 13;
A-B represents a linkage selected from C(O)NR3, CH2NR3, C(O)CH2 and NR3C(O), wherein R3 is hydrogen or as defined below;
Y is CH(R5) or N(R5), wherein R5 is hydrogen or as defined below;
Z is (CH2)2, C(R6)(R7) or N(R7), wherein R6 is hydrogen or methyl and R7 is as defined below;
Z1 is (CH2)2, C(R6)(R8) or N(R8), wherein R6 is hydrogen or methyl and R8 is as defined below;
R1 is hydrogen, alkyloxycarbonylalkanoyl, alkyloxycarbonyl, alkanoyl (optionally substituted with a radical selected from carboxy, alkyloxycarbonyl and heterocycloalkylalkanoylamino), cycloalkylcarbonyl, heterocycloalkylcarbonyl (optionally substituted with a radical selected from hydroxy, alkyl, alkanoyl, alkyloxycarbonyl, arylalkyloxycarbonyl and heterocycloalkylcarbonyl), arylalkyloxycarbonyl, carbamoyl, alkylcarbamoyl, dialkylcarbamoyl, arylcarbamoyl, arylalkylcarbamoyl, arylalkanoyl, aroyl, alkylsulfonyl, dialkylaminosulfonyl, arylsulfonyl or heteroarylsulfonyl;
R7 and R8 are independently hydrogen, alkyl (optionally substituted with a radical selected from hydroxy, amino, alkylamino, dialkylamino, uriedo, mercapto, alkylthio, carboxy, carbamoyl, alkylcarbamoyl, dialkylcarbamoyl, alkylsulfonyl and guanidino, or a protected derivative thereof), cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, a group selected from aryl and arylalkyl (which group is optionally substituted at its aryl ring with one to three radicals selected from hydroxy, amino, guanidino, halo, optionally halo-substituted alkyl, alkyloxy and aryl, or a protected derivative thereof) or together with an adjacent R3 or R5 forms a divalent radical selected from a divalent radical selected from (C3-4)methylene and 1,2-phenylenedimethylene (which radical is optionally substituted with hydroxy, or a protected derivative thereof, or oxo); and
R9 is cyano, C(O)OR10, P(O)(OR10)2, S(O)(NR10)R10, C(O)R11, S(O)R11, C(O)NR12R13, S(O)2NR12R13, C(O)NHR14 or S(O)2NHR14, wherein each R10 is independently hydrogen, alkyl (optionally substituted with one or more radicals selected from amino, halo, hydroxy, alkyloxy, nitro, alkylsulfonyl and arylsulfonyl, or a protected derivative thereof), cycloalkyl, cycloalkylalkyl or a group selected from aryl and arylalkyl (which group is optionally substituted at its aryl ring with one to two radicals selected from amino, halo, hydroxy, optionally halo-substituted alkyl, alkyloxy, nitro, alkylsulfonyl and arylsulfonyl, or a protected derivative thereof), R11 is hydrogen, alkyl, perfluoroalkyl, cycloalkyl, cycloalkylalkyl, perfluoroaryl, perfluoroarylakyl or a group selected from aryl and arylalkyl (which group is optionally substituted at its aryl ring with one to two radicals selected from amino, halo, hydroxy, optionally halo-substituted alkyl, alkyloxy, nitro, alkylsulfonyl and arylsulfonyl, or a protected derivative thereof), R12 and R13 are independently hydrogen, alkyl, cycloalkyl, cycloalkylalkyl, aryl or aralkyl and R14 is C(O)OR10, in which R10 is as defined above, or a group selected from Formula (a) and (b):
3
wherein each n, A, B, Y, Z, R1 and R10 are as defined above in claim 4; or a pharmaceutically acceptable salt, isomer or mixtureof isomers thereof.
8. The method of claim 7, wherein said cathepsin S inhibitor is a compound, wherein each R1 is 1-piperizinylcarbonyl, 4-methyl-1-piperazinylcarbonyl or 4-morpholinylcarbonyl; R8 is 2-phenylethyl; and R7 is optionally substituted benzyl, 1-naphthylmethyl or 2-naphthylmethyl.
9. The method of claim 8, wherein said cathepsin S inhibitor is a compound, wherein R1 is 4-morpholinylcarbonyl, R1 is 2-phenylethyl, R7 is benzyl and R1 is benzylcarbamoyl namely N2-4-(morpholinylcarbonyl)-N1-)3-phenyl-1S-(2-benzylcarbamoylethyl)propyl-L-phenylalaninamide.
10. A method of claim 1, wherein said cathepsin S inhibitor is a compound of formula:
4
wherein A and X are N-substituents selected from the group consisting of acyl, acyl peptidyl, alkyloxycarbonyl, alkyloxycarbonyl peptidyl, sulfonyl, peptidyl, sulfamoyl, sulfamoyl peptidyl, sulfinyl, sulfinyl peptidyl, carbamoyl, and carbamoyl peptidyl;
R1 is (a) an amino acid side chain or (b) hydrogen;
R2 is (a) an amino acid side chain or (b) hydrogen, wherein either (1) both R1 and R2 are hydrogen, or (2) one of R1 or R2 is an amino acid side chain and the other one of R1 and R2 is hydrogen; and
R3 and R4 are hydrogen, or are bonded together to form ethylene or substituted ethylene;
wherein said ethylene substituent is an amino acid side chain.
11. A method of claim 1, wherein said cathepsin S inhibitor is a compound of formula:
5
wherein A is a N-substituent selected from the group consisting of acyl peptidyl, alkyloxycarbonyl peptidyl, peptidyl, sulfamoyl peptidyl, sulfinyl peptidyl, and carbamoyl peptidyl; X is a N-substituent selected from the group consisting of acyl, acyl peptidyl, alkyloxycarbonyl, alkyloxycarbonyl peptidyl, sulfonyl, sulfonyl peptidyl, peptidyl, sulfamoyl, sulfamoyl peptidyl, sulfinyl, sulfinyl peptidyl, carbamoyl, and carbamoyl peptidyl;
R1 is hydrogen; and
R2 is an amino acid side chain.
12. A method of claim 1, wherein said cathepsin S inhibitor is a compound of formula:
6
wherein A and X are N-substituents selected from the group consisting of C(O)R7 (acyl), acyl peptidyl, C(O)OR8 (alkyloxycarbonyl), alkyloxycarbonyl peptidyl, S(O)2R9 (sulfonyl), peptidyl, S(O)2NR10R11, (sulfamoyl), sulfamoyl peptidyl, S(O)R9 (sulfinyl), sulfinyl peptidyl, C(O)NR10R11 (carbamoyl), and carbamoyl peptidyl;
R7 is selected from the group consisting of (C1-5)alkyl, (C3-7)cycloalkyl, (C3-7)cycloalkyl(C1-5)alkyl, (C3-7)cycloalkyl(C1-5)alkenyl, hetero(C3-7)cycoalkyl, (C5-14)aryl, substituted(C5-14)aryl, (C7-12)aralkyl, and substituted(C7-12)aralkyl; wherein said hetero group is selected from the group consisting of hydroxy, (C1-5)alkyl, hetero(C3-7)cycloalkyl, (C1-5)alkanoyl, (C1-5)alkoxycarbonyl, (C5-14)aryl(C1-5)alkoxycarbonyl, and hetero(C3-7)cycloalkylcarbonyl;
R8 is selected from the group consisting of (C1-5)alkyl (optionally substituted with a member of the group consisting of hydroxy, (C1-5)alkoxy, amino, and halogens of atomic number 9-35), (C3-7)cycloalkyl, (C3-7)cycloalkyl(C1-5)alkyl, (C3-7)cycloalkyl(C1-5)alkenyl, (C5-14)aryl, substituted(C5-14)aryl, (C7-12)aralkyl, and substituted(C7-12)aralkyl;
R9 is selected from the group consisting of (C1-5)alkyl (optionally substituted with a member of the group consisting of hydroxy, (C1-5)alkoxy, amino, and halogens of atomic number 9-35), (C3-7)cycloalkyl, (C3-7)cycloalkyl(C1-5)alkyl, (C3-7)cycloalkyl(C1-5)alkenyl, (C5-14)aryl, substituted(C5-14)aryl, (C7-12)aralkyl, and substituted(C7-12)aralkyl;
R10 and R11 are independently selected from the group consisting of hydrogen, (C1-5)alkyl, (C3-7)cycloalkyl, (C3-7)cycloalkyl(C1-5)alkyl, (C5-14)aryl, substituted(C5-14)aryl, (C7-12)aralkyl, substituted(C7-12)aralkyl; di(C1-5)alkyl, (C1-5)alkyl(C7-12)aralkyl; or R10 and R11 are bonded to form a 5 or 6 membered alicyclic or heteroalicylic ring moieties;
Peptidyl is 1-10 amino acids;
said substituents of said substituted aryl and substituted aralkyl are 1 or 2 members of the group consisting of (C1-5)alkyl, (C1-5)alkoxy, halogens of atomic number 9-35, hydroxy, and amino;
R1 is (a) an amino acid side chain or (b) hydrogen;
R2 is (a) an amino acid side chain or (b) hydrogen, wherein either (1) both R, and R2 are hydrogen, or (2) one of R1 or R2 is an amino acid side chain and the other one of R1 and R2 is hydrogen; and
R3 and R4 are hydrogen, or are bonded together to form ethylene or substituted ethylene wherein said ethylene substituent is an amino acid side chain.
13. A method of claim 1, wherein said cathepsin S inhibitor is a compound of formula:
7
wherein A and X are independently R13X1;
R13 is selected from the group consisting of hydrogen, alkyloxycarbonylalkanoyl of overall 3-10 carbon atoms, (C1-9)alkyloxycarbonyl, (C2-10)alkanoyl (optionally substituted with a radical selected from carboxy, (C1-9)alkyloxycarbonyl and hetero(C4-8)cycloalkyl(C2-10)alkanoylamino), (C4-8)cycloalkylcarbonyl, hetero(C4-8)cycloalkylcarbonyl (optionally substituted with a radical selected from hydroxy, (C1-5)alkyl, hetero(C4-8)cycloalkyl, (C1-5)alkanoyl, (C1-5)alkyloxycarbonyl, (C6-10)aryl(C1-5)alkyloxycarbonyl and hetero(C4-8)cycloalkylcarbonyl), (C6-10)aryl(C1-5)alkyloxycarbonyl, carbamoyl, (C1-5)alkylcarbamoyl, di(C1-5)alkylcarbamoyl, (C6-10)arylcarbamoyl, (C6-10)aryl(C1-5)alkylcarbamoyl, (C6-10)aryl(C1-5)alkanoyl, (C7-11)aroyl, (C1-10)alkylsulfonyl, (C6-10)arylsulfonyl, (C6-10)aryl(C1-5)alkylsulfonyl, (C1-5)alkylsulfamoyl, di(C1-5)alkylsulfamoyl, (C6-10)arylsulfamoyl, (C1-5)alkylsulfinyl, di(C1-5)alkylaminosulfinyl, and (C6-10)arylsulfinyl;
X1 is a bond or a divalent radical of formula (a) or (b):
8
n is 0 to 9; X3-X4 represents a linkage selected from C(O)NR14, CH2NR14, C(O)CH2 and NR14C(O);
Y is CH(R14) or NR14;
Z is (CH2)2, C(R15)(R16) or N(R16);
R14 is hydrogen or as defined below;
R15 is hydrogen or methyl;
each R16 is independently hydrogen, (C1-5)alkyl (optionally substituted with a radical selected from hydroxy, (C1-5)alkyloxy, amino, (C1-5)alkylamino, di(C1-5)alkylamino, uriedo, (C1-5) alkyluriedo, mercapto, (C1-5)alkylthio, carboxy, carbamoyl, (C1-5)alkylcarbamoyl, di(C1-5)alkylcarbamoyl, (C1-5)alkylsulfinyl, (C1-5)alkylsulfonyl, guanidino, P(O)(OR12)2, OP(O)(OR12)2 or OP(O)(R12)2, (C3-7)cycloalkyl, (C3-7)cycloalkyl(C1-5)alkyl, (C5-14)aryl, (C5-14)aryl(C1-5)alkyl (which group is optionally substituted at its aryl ring with one to three radicals selected from hydroxy, amino, guanidino, a halogen, optionally halogen substituted (C1-5)alkyl, (C1-5)alkyloxy and (C5-14)aryl, or a protected derivative thereof) or together with an adjacent R14 forms a divalent radical selected from (C3-4)methylene and 1,2-phenylenedimethylene (which radical is optionally substituted with hydroxy, or a protected derivative thereof, or oxo), with the proviso X and A are not both hydrogen;
each R12 is independently hydrogen or (C1-5)alkyl or a protected derivative thereof;
R1 and R2 are both hydrogen or one of R1 or R2 is cyano, carboxy, (C1-5)alkyloxycarbonyl, (C1-5)alkanoyl, carbamoyl, (C1-5)alkylcarbamoyl, di(C1-5)alkylcarbamoyl, (C1-5)alkyloxy((C1-5)alkyl)carbamoyl, amino(C1-5)alkylcarbamoyl, R16, as defined above, or R13X2, wherein R13 is as defined above and X2 is a divalent radical of formulae (a) or (b), as defined above;
R3 and R4 are hydrogen or together form optionally substituted ethylene, wherein said ethylene substituent is an amino acid side chain or are independently R14, as defined above; or a pharmaceutically acceptable salt, isomer or mixture of isomers thereof.
14. A method of claim 1, wherein said CatS inhibitor is a compound of formula:
9
wherein:
R is optionally substituted (aryl, lower alkyl, lower alkenyl, lower alkynyl, or heterocyclyl); R2 and R3 are independently hydrogen, or optionally substituted lower alkyl, cycloalkyl, bicycloalkyl, or (aryl, biaryl, cycloalkyl or bicycloalkyl)lower alkyl; or R2 and R3 together represent lower alkylene, optionally interrupted by O, S or NR6, so as to form a ring with the carbon atom to which they are attached
wherein R6 is hydrogen, lower alkyl or aryl-lower alkyl; or either R2or R3 are linked by lower alkylene to the adjacent nitrogent to form a ring; R4 and R5 are independently H, or optionally substituted (lower alkyl, aryl-lower alkyl), C(O) OR7, or C(O)NR7R8, wherein
R7 is optionally substituted (lower alkyl, aryl, aryl-lower alkyl, cycloalkyl, bicycloalkyl or heterocyclyl), and
R8 is H, or optionalloy substituted (lower alkyl, aryl, aryl-lower alkyl, cycloalkyl, bicycloalkyl or heterocyclyl), or R4 and R5 together represent lower alkylene, optionally interrupted by O, S or NR6 so as to form a ring with the carbon atom to which they are attached
wherein R6 is hydrogen, lower alkyl or aryl-lower alkyl, or R4 is H or optionally substituted lower alkyl and R5 is a substituent of formula-X2(Y1)n(Ar)PQZ wherein
Y1 is O, S, SO, SO2, N(R6)SO2, NR6, SO2NR6, CONR6 or NR6CO;
n is zero or one;
p is zero or one;
X2 is lower alkylene; or when n is zero, X2 is also C2-C7-alkylene interrupted by O, S, SO, SO2, NR6, SO2NR6, CONR6 or NR6CO;
wherein R6 is hydrogen, lower alkyl or aryl-lower alkyl;
Ar is arylene;
Z is hydroxy, acyloxy, carboxyl, esterified carboxyl, amidated carboxyl, aminosulfonyl, (lower alkyl or aryl-lower alkyl)aminosulfonyl, or (lower alkyl or aryl-lower alkyl)sulfonylaminocarbonyl; or Z is tetrazolyl, triazolyl or imidazolyl; Q is direct bond, lower alkylene, Y1-lower alkylene or C2-C7-alkylene interrupted by Y1;
X1 is C(O), C(S), S(O), S(O)2, or P(O)(OR6), wherein R6 is as defined above;
Y is oxygen or sulfur;
L is optionally substituted -Het-, -Het-CH2 or CH2-Het-,
wherein Het is a hetero atom selected from O, N or S, and x is zero or one;
and aryl in the above definitions represents carboxyclic or heterocyclic aryl; or a physiologically-acceptable and -cleavable ester or a salt thereof.
15. A method of claim 14, provided that when R is lower alkyl not substituted by aryl, one of R4 or R5 is a substituent of formula X2(Y1)n(Ar)PQZ;
provided that when x is one, L is O, or CH2O and X1 is C(O), either one of R4 or R5 is a substituent of formula X2(Y1)n(Ar)pQZ, or R is not unsubstituted phenyl;
provided that when R2R4R5H, x is zero and X1 is C(O), R3 is not H, CH3, CH(CH3)2, CH2CH(CH3)2, CH2COOH, or CH2COOCH2CH3, when R is unsubstituted phenyl,
R3 is not H, CH(CH3)2, or CH2CH(CH3)2, when R is 4-aminophenyl or 4-nitrophenyl,
R3 is not H when R is 3-aminophenyl, 3-nitrophenyl 2-chloropyridin-4-yl, or vinyl or
R3 is not CH2CH2SCH3 when R is pyridin-3-yl or 2-chloropyridin-4-yl, provided that when R2R3R4H, x is zero and X1 is C(O) and R is phenyl,
R5 is not CH(CH3)2,
provided that when R3R4H, R5 is CH2CH2COOH, x is zero and X1 is C(O),
R2 does not form a heterocyclic ring with the adjacent nitrogen atom, and provided that when R2R3R4R5H, x is zero and X1 is SO2, R is not 4-methylphenyl.
16. A method of claim 1, wherein said CatS inhibitor is a compound of formula III
10
wherein
R30 is an acyl group derived from an organic carboxylic, carbonic, carbamic or sulfonic acid;
R32 and R33 are independently hydrogen, lower alkyl, cycloalkyl, bicycloalkyl, or (aryl, biaryl, cycloalkyl or bicycloalkyl)-lower alkyl; or R32 and R33 together represent lower alkylene so as to form a ring together with the carbon to which they are attached;
R34 is hydrogen or lower alkyl;
X2, Y1, Ar, Q, Z, n and p are as defined in claim 14; or a pharmaceutically acceptable salt or ester thereof.
17. A method of claim 16, wherein said CatS inhibitor is compound wherein
(a) p is one;
(b) Y1 is O, S, SO, SO2, N(R6)SO2 or NR6; and
(c) X2 is lower alkylene; or when n is zero, X2 is also C2-C7-alkylene interrupted by O, S, SO, SO2 or NR6,
(d) R30 is an acyl group derived from an organic carboxylic, carbamic, or sulfonic acid,
(e) and pharmaceutically acceptable salts and esters thereof.
18. A method of claim 14, wherein said CatS inhibitor is a compound of the formula:
11
wherein
R40 is substituted phenyl or heterocyclic aryl, (mono- or di-carbocyclic or heterocyclic aryl)-lower alkyl or lower alkenyl, or heterocyclyl;
R42 is hydrogen or lower alkyl;
R43 is carbocyclic or heterocyclic aryl or lower alkyl;
R44 and R45 are independently hydrogen or lower alkyl; or
R44 and R45 combined represent lower alkylene;
Or a pharmaceutically acceptable salt or ester thereof.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1. An articulated sole structure comprising:
a footwear sole structure spanning portion extending longitudinally along the length of the sole structure and transversely between the medial and lateral sides of the sole structure; and
an articulated portion located below the spanning portion and comprising
a plurality of sipes extending upward into the articulated portion from a bottom surface of the articulated portion and forming a hexagonal pattern on the bottom surface of the articulated portion, and
a plurality of discrete hexagonally-shaped sole elements extending downward from the spanning portion, wherein individual hexagonally-shaped sole elements are at least partially defined by one or more sipes of the plurality of sipes;
wherein a first sipe depth of one or more sipes located in a forefoot region and of one or more sipes located in a heel region of the sole structure is greater than a second sipe depth of one or more sipes located in a forefoot region of the sole structure.
2. The articulated sole structure of claim 1 wherein:
one of the hexagonally-shaped sole elements comprises a plurality of radial sipes extending upward into the articulated portion from the bottom surface of the articulated portion; and
individual radial sipes of the plurality of radial sipes extend from respective vertices of the hexagonally-shaped sole element toward a center of the hexagonally-shaped sole element such that the plurality of radial sipes subdivide the hexagonally-shaped sole element into at least one diamond-shaped sole element portion.
3. The sole structure of claim 2 wherein the plurality of radial sipes includes three radial sipes that subdivide the hexagonally-shaped sole element into three diamond-shaped sole element portions.
4. The sole structure of claim 1 further comprising:
a plurality of hexagonal lugs extending downward from the bottom surface of the articulated sole portion; and
individual hexagonal lugs of the plurality of hexagonal lugs are connected to and extend downward from one of the hexagonal sole elements.
5. The sole structure of claim 1 wherein:
individual hexagonal lugs of the plurality of hexagonal lugs have an edge-to-edge diameter of about 11 mm to about 13 mm; and
individual hexagonal lugs of the plurality of hexagonal lugs have a height of about 1 mm to about 3 mm.
6. The sole structure of claim 1 wherein one of the hexagonally-shaped sole elements includes sides that are about the same length such that the hexagonally-shaped sole element resembles a regular hexagon.
7. The sole structure of claim 6 wherein the hexagonally-shaped sole element has an edge-to-edge diameter of about 18 mm to about 20 mm.
8. The sole structure of claim 1 wherein:
one or more of the sipes located in the forefoot region near a forward end of the forefoot region of the sole structure have a sipe depth of about 2 mm to about 3 mm;
one or more of the sipes located in the forefoot region near a rear end of the forefoot region of the sole structure have a sipe depth of abut 7 mm to about 8 mm;
one or more of the sipes located in a midfoot region of the sole structure have a sipe depth of about 7 mm to about 10 mm; and
one or more of the sipes located in a heel region of the sole structure have a sipe depth of about 10 mm.
9. The sole structure of claim 8 further comprising at least one outsole element covering a portion of the articulated portion.
10. The articulated sole structure of claim 1 further comprising:
a plurality of lateral sipes extending upward into the articulated portion from a bottom surface of the articulated portion and extending in a transverse direction from the lateral side toward the medial side of the articulated portion; and
a plurality of medial sipes extending upward into the articulated portion from the bottom surface of the articulated portion and extending in a transverse direction from the medial side toward the lateral side of the articulated portion.
11. The articulated sole structure of claim 10 further comprising:
at least one mediolateral sipe located in a forefoot region of the articulated portion and extending across the entire width of the of the articulated portion in a transverse direction from a medial edge of the articulated portion to a lateral edge of the articulated portion; and
wherein the at least one mediolateral sipe bisects at least one of the hexagonally-shaped sole elements.
12. The articulated sole structure of claim 11 wherein:
the mediolateral sipe is one of three mediolateral sipes located in the forefoot region of the articulated portion; and
the three mediolateral sipes are substantially parallel to each other.
13. The articulated sole structure of claim 1 further comprising:
a curved sipe extending sideward into a side of the articulated sole structure;
wherein the curved sipe extends along the side of the articulated sole structure through at least a portion of a heel region, through a midfoot region, and through at least a portion of a forefoot region of the articulated sole structure; and
wherein the curved sipe is located at least partially above the articulated portion.
14. The articulated sole structure of claim 13 wherein the zig-zag sipe comprises:
a first plurality of vertices positioned proximate a top edge of the articulated portion; and
a second plurality of vertices positioned away from the top edge of the articulated portion and adjacent to individual sipes extending upward into the articulated portion from the bottom surface of the articulated portion.
15. An article of footwear comprising:
an upper;
a flexible midsole coupled to the upper wherein the midsole includes a plurality of transverse sipes and a plurality of oblique sipes extending upward into the midsole from a bottom surface of the midsole and wherein the midsole includes a plurality of discrete hexagonally-shaped sole elements defined by the plurality of transverse sipes and the plurality of oblique sipes;
wherein individual hexagonally-shaped sole elements are located in a region extending across at least a portion of a heel region, through a midfoot region, and through at least a portion of a forefoot region of the midsole;
wherein one or more transverse sipes and one or more oblique sipes located near a forward end of a forefoot region of the sole structure have a sipe depth of about 2 mm to about 3 mm;
wherein one or more transverse sipes and one or more oblique sipes located near a rear end of the forefoot region have a sipe depth of about 7 mm to about 8 mm;
wherein one or more transverse sipes and one or more oblique sipes located in a midfoot region of the sole structure have a sipe depth of about 7 mm to about 10 mm; and
wherein one or more transverse sipes and one or more oblique sipes located in a heel region of the sole structure have a sipe depth of about 10 mm.
16. The article of footwear of claim 15 wherein:
the plurality of hexagonally-shaped sole elements includes a first hexagonally-shaped sole element that is located in the heel region of the midsole and that includes a first hexagonally-shaped lug extending downward from the first hexagonally-shaped sole element;
the plurality of hexagonally-shaped sole elements includes a second hexagonally-shaped sole element that is located in the forefoot region of the midsole and that includes a second hexagonally-shaped lug extending downward from the second hexagonally-shaped sole element; and
the plurality of hexagonally-shaped sole elements includes one or more hexagonally-shaped sole elements located in the midfoot region of the midsole that do not include a hexagonally shaped lug.
17. The article of footwear of claim 15 wherein:
one of the hexagonally-shaped sole elements comprises a plurality of radial sipes extending upward into the midsole from the bottom surface of the midsole;
individual radial sipes of the plurality of radial sipes extend from respective vertices of the hexagonally-shaped sole element toward a center of the hexagonally-shaped sole element such that the plurality of radial sipes subdivide the hexagonally-shaped sole element into at least one diamond-shaped sole element portion; and
the plurality of radial sipes are merged with each other at the center of the hexagonally-shaped sole element such that the radial sipes are contiguous with one another.
18. The article of footwear of claim 15 wherein the midsole further includes:
a first plurality of discrete non-hexagonal sole elements located along a lateral edge of the midsole that are at least partially defined by individual oblique sipes of the plurality of oblique sipes and at least one lateral sipe that extends upward into the midsole from the bottom surface of the midsole and in a transverse direction from a lateral side toward a medial side of the midsole;
a second plurality of discrete non-hexagonal sole elements located along a medial edge of the midsole that are at least partially defined by individual oblique sipes of the plurality of oblique sipes and at least one medial sipe extending upward into the midsole from the bottom surface of the midsole and in a transverse direction from the medial side toward the lateral side of the midsole; and
wherein individual non-hexagonal sole elements of the first and second plurality of non-hexagonal sole elements share at least one edge with one of the hexagonally-shaped sole elements of the plurality of hexagonally-shaped sole elements.
19. The article of footwear of claim 15 further comprising:
at least one outsole element covering a portion of the midsole in the heel region of the midsole; and
at least one outsole element covering a portion of the midsole in the forefoot region of the midsole.
20. The article of footwear of claim 15 wherein:
individual transverse sipes of the plurality of transverse sipes have a length of about 10 mm to about 11 mm;
individual oblique sipes of the plurality of oblique sipes have a length of about 10 mm to about 12 mm; and
individual hexagonally-shaped sole elements of the plurality of hexagonally-shaped sole elements have an edge-to-edge diameter of about 18 mm to about 20 mm.
21. An articulated sole structure comprising:
an upper;
a footwear sole structure attached to the upper comprising a spanning portion extending longitudinally along the length of the sole structure and transversely between the medial and lateral sides of the sole structure and an articulated portion located below the spanning portion; and
a curved sipe extending sideward into a side of the sole structure and extending along the side of the sole structure through at least a portion of a heel region, through a midfoot region, and through at least a portion of a forefoot region of the articulated sole structure;
wherein the curved sipe permits the spanning portion to separate from the articulated portion in response to tension on the upper; and
wherein the curved sipe forms opposing contoured surfaces in the sole structure that abut against each other in response to twisting of the sole structure and resist the twisting of the sole structure.
22. The articulated sole structure of claim 21 wherein the curved sipe is a first curved sipe that extends sideward into a lateral side of the articulated sole structure and further comprising a second curved sipe that extends sideward into a medial side of the articulated sole structure and along the medial side of the sole structure through at least a portion of the heel region, through the midfoot region, and through at least a portion of the forefoot region.
23. The articulated sole structure of claim 22 wherein the first curved sipe and the second curved sipe each have a depth of about 1 mm to about 5 mm.
24. The articulated sole structure of claim 21 further comprising:
a plurality of sipes extending upward into the articulated portion from a bottom surface of the articulated portion; and
a plurality of discrete sole elements extending downward from the spanning portion, wherein individual sole elements are at least partially defined by one or more sipes of the plurality of sipes.
25. The articulated sole structure of claim 24 wherein:
the plurality of sipes form a hexagonal pattern on the bottom surface of the articulated portion; and
the plurality of discrete sole elements each have a hexagonal shape.